edaravone has been researched along with Adult Spinal Muscular Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, S | 1 |
| Funato, M | 1 |
| Ohuchi, K | 1 |
| Kameyama, T | 1 |
| Inagaki, S | 1 |
| Seki, J | 1 |
| Kawase, C | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Kaneko, H | 1 |
| Hara, H | 1 |
| Kiernan, MC | 1 |
2 other studies available for edaravone and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model.
Topics: Animals; Antipyrine; Apoptosis; Disease Models, Animal; Edaravone; Fibroblasts; Humans; Induced Plur | 2017 |
Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.
Topics: Amyotrophic Lateral Sclerosis; Benzamides; Edaravone; Humans; Muscular Atrophy, Spinal; Neuroprotect | 2018 |